The Latest Headlines at ETF Daily News
Evercore ISI Boosts Western Union (NYSE:WU) Price Target to $14.00
Western Union (NYSE:WU – Free Report) had its target price hoisted by Evercore ISI from $13.00 to $14.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has an in-line rating on the credit services... More of this article »
Western Union (NYSE:WU) PT Raised to $14.00
Western Union (NYSE:WU – Get Free Report) had its price target hoisted by research analysts at Evercore ISI from $13.00 to $14.00 in a report released on Tuesday, Benzinga reports. The firm currently has an “in-line”... More of this article »
PennantPark Floating Rate Capital (NASDAQ:PFLT) Stock Rating Reaffirmed by JMP Securities
JMP Securities restated their market outperform rating on shares of PennantPark Floating Rate Capital (NASDAQ:PFLT – Free Report) in a report released on Tuesday morning, Benzinga reports. JMP Securities currently has a $12.50... More of this article »
PennantPark Floating Rate Capital’s (PFLT) Market Outperform Rating Reiterated at JMP Securities
PennantPark Floating Rate Capital (NASDAQ:PFLT – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by research analysts at JMP Securities in a research report issued to clients and investors... More of this article »
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $105.00 price target... More of this article »
Praxis Precision Medicines’ (PRAX) “Buy” Rating Reiterated at HC Wainwright
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,... More of this article »
R1 RCM (NASDAQ:RCM) Earns Overweight Rating from Morgan Stanley
Morgan Stanley reissued their overweight rating on shares of R1 RCM (NASDAQ:RCM – Free Report) in a research report released on Tuesday morning, Benzinga reports. They currently have a $17.00 target price on the healthcare provider’s... More of this article »
Regeneron Pharmaceuticals’ (REGN) “Buy” Rating Reiterated at Truist Financial
Truist Financial reaffirmed their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $1,135.00 price objective on the biopharmaceutical... More of this article »
R1 RCM (NASDAQ:RCM) Stock Rating Reaffirmed by Morgan Stanley
R1 RCM (NASDAQ:RCM – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Morgan Stanley in a research note issued on Tuesday, Benzinga reports. They presently have a $17.00 price... More of this article »
Red Violet (NASDAQ:RDVT) Research Coverage Started at B. Riley
B. Riley started coverage on shares of Red Violet (NASDAQ:RDVT – Free Report) in a research report released on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $25.00 price objective on the stock. Red Violet... More of this article »
B. Riley Begins Coverage on Red Violet (NASDAQ:RDVT)
Research analysts at B. Riley began coverage on shares of Red Violet (NASDAQ:RDVT – Get Free Report) in a research note issued on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $25.00 price target... More of this article »
SoFi Technologies (NASDAQ:SOFI) PT Lowered to $12.00
SoFi Technologies (NASDAQ:SOFI – Get Free Report) had its price objective cut by stock analysts at Jefferies Financial Group from $15.00 to $12.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “buy”... More of this article »
Stoke Therapeutics (NASDAQ:STOK) Given New $17.00 Price Target at Wedbush
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) had its target price boosted by investment analysts at Wedbush from $13.00 to $17.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has an “outperform”... More of this article »